The choice of the dose of an anticancer drug is established in first-in-human, dose-escalation, phase 1 clinical trials involving patients with cancer for whom standard-of-care treatments are often no ...

For decades, the U.S. Food and Drug Administration's adverse events system has been the primary surveillance tool for monitoring potential side effects caused by drugs after they get on the market.